REDWOOD CITY, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will provide a corporate update at two upcoming investor conferences.
- BIO CEO and Investor Conference – New York
OncoMed’s corporate presentation is scheduled to take place at 10:30 a.m. ET on February 8, 2016.
- Leerink Partners 5th Annual Global Healthcare Conference – New York
Paul Hastings will provide a fireside chat on Thursday, February 11 at 8:30 a.m. ET.
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcasts will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin-LGR. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate that is part of OncoMed’s collaboration with Celgene (IO#2) toward clinical trials in the 2016-2017 timeframe.
Please see the company’s website at www.oncomed.com for additional information.
Contact:
Media & Investors
OncoMed Pharmaceuticals
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
michelle.corral@oncomed.com
(650) 995-8373
